Quick Read Alphabet (GOOG,GOOGL) holds a portfolio of 37 stocks worth $2.5B to $3B through its venture arms GV and CapitalG.

Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 Dr. Kathiresan continued, “In addition, ...

Verve ended the third quarter of 2024 with $539.9 million in cash, cash equivalents, and marketable securities. Verve expects its capital position to be sufficient to fund its operations through 2026.

Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing ...

Verve Therapeutics grants equity awards to new employees as part of its stock incentive plan, promoting talent in genetic medicine development. Verve Therapeutics announced on June 2, 2025, that it ...

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028. Sarepta Therapeutics falls sharply ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive ...

Verve Therapeutics Inc (NASDAQ:VERV) on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of ...